This was the stock's second consecutive day of losses.
The stock's fall snapped a four-day winning streak.
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
